BACKGROUND: The combination of granulocyte-colony-stimulating factor (G-CSF) and dexamethasone is an effective granulocyte mobilization regimen. The short-term side effects of G-CSF are well studied, but the potential long-term effects of repeated G-CSF stimulation in unrelated volunteer granulocyte donors have not been reported. STUDY DESIGN AND METHODS: Donors who had received G-CSF three or more times for granulocytapheresis between 1994 and 2002 were identified and attempts were made to contact them if they were no longer active donors. They were matched with control platelet (PLT) donors for sex, age, and approximate number of cytapheresis donations. A health history was obtained and complete blood counts (CBCs) and C-reactive protein (CRP) determined where feasible. RESULTS: Ninety-two granulocyte donors were identified, and 83 of them were contacted. They contributed to 1120 granulocyte concentrates, or a mean of 13.5 granulocytapheresis procedures per donor (and a mean of 87.5 plateletpheresis procedures per donor). There was no difference in CBCs between the granulocyte donors and the control PLT donors. There was no difference in CRP between the two groups, and no difference in pre- and post-G-CSF CRP in a subset of 22 granulocyte donors. Predefined health events included malignancies, coronary artery disease, and thrombosis. At a median 10-year follow-up, there were seven such events in the granulocyte donors and five in the PLT donors. CONCLUSION: Although the number of granulocyte donors studied is small and continued surveillance of healthy individuals after G-CSF is prudent, our data suggest that G-CSF/dexamethasone stimulation appears to be safe.
BACKGROUND: The combination of granulocyte-colony-stimulating factor (G-CSF) and dexamethasone is an effective granulocyte mobilization regimen. The short-term side effects of G-CSF are well studied, but the potential long-term effects of repeated G-CSF stimulation in unrelated volunteer granulocyte donors have not been reported. STUDY DESIGN AND METHODS: Donors who had received G-CSF three or more times for granulocytapheresis between 1994 and 2002 were identified and attempts were made to contact them if they were no longer active donors. They were matched with control platelet (PLT) donors for sex, age, and approximate number of cytapheresis donations. A health history was obtained and complete blood counts (CBCs) and C-reactive protein (CRP) determined where feasible. RESULTS: Ninety-two granulocyte donors were identified, and 83 of them were contacted. They contributed to 1120 granulocyte concentrates, or a mean of 13.5 granulocytapheresis procedures per donor (and a mean of 87.5 plateletpheresis procedures per donor). There was no difference in CBCs between the granulocyte donors and the control PLT donors. There was no difference in CRP between the two groups, and no difference in pre- and post-G-CSFCRP in a subset of 22 granulocyte donors. Predefined health events included malignancies, coronary artery disease, and thrombosis. At a median 10-year follow-up, there were seven such events in the granulocyte donors and five in the PLT donors. CONCLUSION: Although the number of granulocyte donors studied is small and continued surveillance of healthy individuals after G-CSF is prudent, our data suggest that G-CSF/dexamethasone stimulation appears to be safe.
Authors: A M Cavallaro; K Lilleby; I Majolino; R Storb; F R Appelbaum; S D Rowley; W I Bensinger Journal: Bone Marrow Transplant Date: 2000-01 Impact factor: 5.483
Authors: Miguel A Canales; Rosario Arrieta; Ruben Gomez-Rioja; Jesus Diez; Victor Jimenez-Yuste; Fernando Hernandez-Navarro Journal: J Hematother Stem Cell Res Date: 2002-08
Authors: J Bux; U Cassens; T Dielschneider; M Duchscherer; E Edel; H Eichler; C Haas; R Moog; H Peschke; C Peters; I Ryzenkov; P Schlenke; H Ullrich; M Wiesneth Journal: Vox Sang Date: 2003-11 Impact factor: 2.144
Authors: Matthew J Olnes; Andrea Poon; Susan J Miranda; Loretta Pfannes; Zachary Tucker; Kelsey Loeliger; Hesed Padilla-Nash; Yu Ying Yau; Thomas Ried; Susan F Leitman; Neal S Young; Elaine M Sloand Journal: Transfusion Date: 2011-08-29 Impact factor: 3.157
Authors: A Marmotti; F Castoldi; R Rossi; S Marenco; A Risso; M Ruella; A Tron; A Borrè; D Blonna; C Tarella Journal: Knee Surg Sports Traumatol Arthrosc Date: 2012-08-08 Impact factor: 4.342
Authors: Karen Quillen; Edward Wong; Phillip Scheinberg; Neal S Young; Thomas J Walsh; Colin O Wu; Susan F Leitman Journal: Haematologica Date: 2009-12 Impact factor: 9.941
Authors: Mélanie Demers; Daniela S Krause; Daphne Schatzberg; Kimberly Martinod; Jaymie R Voorhees; Tobias A Fuchs; David T Scadden; Denisa D Wagner Journal: Proc Natl Acad Sci U S A Date: 2012-07-23 Impact factor: 11.205
Authors: Catherine E DeJesus; Jackson Egen; Mark Metzger; Xavier Alvarez; Christian A Combs; Daniela Malide; Zu Xi Yu; Xin Tian; Robert E Donahue Journal: Exp Hematol Date: 2010-11-16 Impact factor: 3.084